Workflow
Rapatha
icon
Search documents
Cramer's Stop Trading: Amgen
CNBC Television· 2025-10-03 14:22
Let's get stop trading with Jim. One thing that some people may have missed came out yesterday was that Amgen had a landmark study that went very well for Rapatha uh lowering cholesterol and therefore do you know helping people's hearts even if you don't have cholesterol. Now I'm on this uh Rapatha because my doctor is basically part of this trial and just said look there's no level of cholesterol that's good.uh they're also they're not doing a study on this but people feel that reduces plaque but I think t ...
Cramer's Stop Trading: Amgen
Youtube· 2025-10-03 14:22
Group 1 - Amgen's recent study on Rapatha demonstrated significant effectiveness in lowering cholesterol, which is beneficial for heart health, even in patients without high cholesterol levels [1][2] - Rapatha is noted for its high cost but is recognized for its efficacy in reducing the risk of heart attacks by managing bad cholesterol levels [2] - The VANC Pharma ETF has experienced its best week since 2009, indicating positive market sentiment towards pharmaceutical stocks [2] Group 2 - There is clarity regarding the Pfizer deal, with Amgen pricing its drugs competitively, which aligns with the administration's goals [3] - The administration's stance appears to have shifted, indicating that the pharmaceutical industry is not viewed as an adversary, which may lead to more favorable conditions for drug pricing [3]